The relationship between apelin and cardiac parameters in patients on peritoneal dialysis: Is there a new cardiac marker?

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Karadag, Serhat ^a   Ozturk, Savas ^a   Gursu, Meltem ^a   Gurdal, Ahmet ^b   Basinoglu, Filiz ^c   Yigit, Servet ^c   Aydin, Zeki ^a   Uzun, Sami ^a   Sumnu, Abdullah ^a   Oflaz, Huseyin ^b   Kazancioglu, Rumeyza ^d  

^a Haseki Training and Research Hospital ^*  (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^d BEZMIALEM VAKIF UNIVERSITY   (Turkey)

Author keywords

Apelin; Echocardiography; Hypervolemia; Peritoneal dialysis

Indexed keywords

ALKALINE PHOSPHATASE; APELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; ANGIOTENSIN RECEPTOR ANTAGONIST; APELIN 36; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MINERAL; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERVOLEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINERAL METABOLISM; PERITONEAL DIALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VERY ELDERLY; YOUNG ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; BONE METABOLISM; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; END STAGE RENAL DISEASE; HEART LEFT ATRIUM; HEMODIALYSIS PATIENT; PROTEIN BLOOD LEVEL; SEX RATIO; URINE VOLUME;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84896738066     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-18     Document Type: Article

References (35)

1. Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients. Miller LM, Sood MM, Sood AR, Reslerova M, Komenda P, Rigatto C, Bueti J, Int Urol Nephrol 2010 42 1007 1014 10.1007/s11255-010-9857-x 20960231
2. Cardiovascular risk in the peritoneal dialysis patient. Krediet RT, Balafa O, Nat Rev Nephrol 2010 6 451 460 10.1038/nrneph.2010.68 20567248
3. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, Giacone G, Cottini E, Tripepi G, Malatino LS, Zoccali C, Nephrol Dial Transplant 2001 16 1459 1464 10.1093/ndt/16.7.1459 11427641
4. US Renal Data System, USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Volume II Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease 2007 http://www.usrds.org
5. Predictors of survival in anuric peritoneal dialysis patients. Jansen MA, Termorshuizen F, Korevaar JC, Dekker FW, Boeschoten E, Krediet RT, Kidney Int 2005 68 1199 1205 10.1111/j.1523-1755.2005.00512.x 16105051
6. A broad-based metabolic approach to study VLDL apoB-100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Prinsen B, Kidney Int 2004 65 1064 1075 10.1111/j.1523-1755.2004.00466.x 14871427
7. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T, Gene 1993 136 355 360 10.1016/0378-1119(93)90495-O 8294032
8. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M, Biochem Biophys Res Commun 1998 251 471 476 10.1006/bbrc.1998.9489 9792798
9. The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF, Arq Bras Cardiol 2008 90 343 349 18516406
10. Immunocytochemical localization of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Kleinz MJ, Skepper JN, Davenport AP, Regul Pept 2005 126 233 240 10.1016/j.regpep.2004.10.019 15664671
11. Apelin: a novel neurohumoral modulator of the cardiovascular system: pathophysiologic importance and potential use as a therapeutic target. Falcao-Pires I, Leite-Moreira AF, Rev Port Cardiol 2005 24 1263 1276 16398242
12. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujiyama M, Regul Pept 2001 99 87 92 10.1016/S0167-0115(01)00236-1 11384769
13. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP, Br J Pharmacol 2001 132 1255 1260 10.1038/sj.bjp.0703939 11250876
14. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Szakodi I, Tavi P, Foldes G, Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysä J, Tóth M, Ruskoaho H, Circ Res 2002 91 434 440 10.1161/01.RES.0000033522.37861.69 12215493
15. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillo W, Dakin C, Sajedi A, Ghatei M, Bloom S, Biochem Biophys Res Commun 2002 291 1208 1212 10.1006/bbrc.2002.6575 11883945
16. Effect of apelin on glomerular hemodynamic function in the rat kidney. Hus-Citharel A, Bouby N, Frugière A, Bodineau L, Gasc JM, Llorens-Cortes C, Kidney Int 2008 74 486 494 10.1038/ki.2008.199 18509323
17. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA, Eur J Heart Fail 2006 8 355 360 10.1016/j.ejheart.2005.10.007 16464638
18. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, Ben-Dor A, Fenster B, Yang E, King JY, Fowler M, Robbins R, Johnson FL, Bruhn L, McDonagh T, Dargie H, Yakhini Z, Tsao PS, Quertermous T, Circulation 2003 108 1432 1439 10.1161/01.CIR.0000091235.94914.75 12963638
19. Apelin and its receptor are expressed in human osteoblasts. Xie H, Tang SY, Cui RR, Huang J, Ren XH, Yuan LQ, Lu Y, Yang M, Zhou HD, Wu XP, Luo XH, Liao EY, Regul Pept 2006 134 118 125 10.1016/j.regpep.2006.02.004 16563531
20. Apelin suppresses apoptosis of human osteoblasts. Xie H, Yuan LQ, Luo XH, Huang J, Cui RR, Guo LJ, Zhou HD, Wu XP, Liao EY, Apoptosis 2007 12 247 254 10.1007/s10495-006-0489-7 17136493
21. Apelin attenuates the osteoblastic differentiation of vascular smooth muscle cells. Shan PF, Lu Y, Cui RR, Jiang Y, Yuan LQ, Liao EY, PLoS One 2011 18 17938
22. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. Ronkainen VP, Ronkainen JJ, Hanninen SL, Leskinen H, Ruas JL, Pereira T, Poellinger L, Vuolteenaho O, Tavi P, FASEB J 2007 21 1821 1830 10.1096/fj.06-7294com 17341685
23. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Foldes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, Mäyränpää M, Sármán B, Seres L, Skoumal R, Lakó-Futó Z, de Châtel R, Ruskoaho H, Tóth M, Biochem Biophys Res Commun 2003 308 480 485 10.1016/S0006-291X(03)01424-4 12914775
24. Apelin and cardiac function in hemodialyzed patients: possible relations? Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M, Am J Nephrol 2006 26 121 126 10.1159/000092122 16549903
25. Evidence for decreased circulating apelin beyond heart involvement in uremic cardiomyopathy. Codognotto M, Piccoli A, Zaninotta M, Mion M, Vertolli U, Tona F, Boffa GM, Am J Nephrol 2007 27 1 6 10.1159/000098430 17204831
26. Reduced apelin levels in lone atrial fibrillation. Ellinor PT, Low AF, Macrae CA, Eur Heart J 2006 27 222 226 16278229
27. Reduced apelin levels in stable angina. Li Z, Bai Y, Jian H, Intern Med 2008 47 1951 1955 10.2169/internalmedicine.47.1287 19015606
28. Apelin serum level in Egyptian patients with chronic hepatitis C. El-Mesallamy HO, Hamdy NM, Rizk HH, El-Zayadi AR, Mediators Inflamm 2011 2011 703031 Epub 22007137
29. Type of arteriovenous fistula, NYHA class and apelin in hemodialyzed patients. Malyszko J, Kozminski P, Malyszko J, Mysliwiec M, Int Urol Nephrol 2011 43 185 190 10.1007/s11255-009-9667-1 19908160
30. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD, Newby DE, Circulation 2010 121 1818 1827 10.1161/CIRCULATIONAHA.109.911339 20385929
31. The role of apelin in cardiovascular function and heart failure. Chandrasekaran B, Dar O, McDonagh T, Eur J Heart Fail 2008 10 725 732 10.1016/j.ejheart.2008.06.002 18583184
32. Adiposity dependent apelin gene expression: relationship with oxidative and inflammation markers. García-Diaz D, Campión J, Milagro FI, Martínez JA, Mol Cell Biochem 2007 305 87 94 10.1007/s11010-007-9531-5 17594060
33. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M, Transplant Proc 2008 40 3466 3469 10.1016/j.transproceed.2008.06.059 19100414
34. Apelin: a potential link between inflammation and cardiovascular disease in end stage renal disease patients. El-Shehaby AM, El-Khatib MM, Battah AA, Roshdy AR, Scand J Clin Lab Invest 2010 70 421 427 10.3109/00365513.2010.504281 20645679
35. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. Zhang H, Xie H, Zhao Q, Xie GQ, Wu XP, Liao EY, Luo XH, Endocrinol Invest 2010 33 707 711